(Q38084203)

28 August 2017

title

Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique (English)

1 reference

28 August 2017

main subject

metastatic breast cancer

1 reference

1 reference

Bonny Parkinson

1

0 references

Rosalie Viney

object named as

Rosalie Viney

series ordinal

3

0 references

Sallie-Anne Pearson

series ordinal

2

object named as

Sallie-Anne Pearson

1 reference

28 August 2017

language of work or name

1 reference

24 February 2013

1 reference

The European Journal of Health Economics

28 August 2017

published in

1 reference

28 August 2017

volume

15

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

93-112

1 reference

https://scigraph.springernature.com/pub.10.1007/s10198-013-0459-2

28 August 2017

exact match

0 references

cites work

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Systematic reviews of economic evaluations: utility or futility?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Trastuzumab beyond progression: a cost-utility analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Health state utilities for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Trastuzumab and metastatic breast cancer: trastuzumab use in Australia--monitoring the effect of an expensive medicine access program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Trastuzumab: a pharmacoeconomic review of its use in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Systematic overview of cost-utility assessments in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Health state utility scores in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-013-0459-2

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic ana

21 January 2018

1 reference

12 December 2020

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

12 December 2020

Is trastuzumab a cost-effective treatment for breast cancer?

1 reference

12 December 2020

Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis

1 reference

12 December 2020

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

12 December 2020

Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.

1 reference

12 December 2020

Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation

1 reference

12 December 2020

A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine

1 reference

12 December 2020

A primer on before-after studies: evaluating a report of a "successful" intervention

1 reference

12 December 2020

Experimental versus observational data in the economic evaluation of pharmaceuticals

1 reference

12 December 2020

10.1007/S10198-013-0459-2

Identifiers

DOI

1 reference

28 August 2017

1 reference